Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
REC-4881
i
Other names:
REC-4881, TAK-733
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(6)
News
Trials
Company:
Recursion Pharma, Takeda
Drug class:
MEK1 inhibitor, MEK2 inhibitor
Related drugs:
‹
cobimetinib (94)
HL-085 (12)
U0126 (10)
IMM-1-104 (5)
FCN-159 (4)
SHR7390 (3)
E6201 (1)
ABM-168 (0)
BI 847325 (0)
PD198306 (0)
TQ-B3234 (0)
cobimetinib (94)
HL-085 (12)
U0126 (10)
IMM-1-104 (5)
FCN-159 (4)
SHR7390 (3)
E6201 (1)
ABM-168 (0)
BI 847325 (0)
PD198306 (0)
TQ-B3234 (0)
›
Associations
(6)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation (NCT06005974)
Phase 2
Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc.
Recruiting
Phase 2
Recursion Pharmaceuticals Inc.
Recruiting
Last update posted :
02/06/2024
Initiation :
01/15/2024
Primary completion :
01/01/2027
Completion :
01/01/2027
APC • RAS • AXIN1
|
APC mutation
|
REC-4881
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login